OncoMatch/Clinical Trials/NCT06750419
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Is NCT06750419 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies 89Zr-TLX250 PET/CT for clear cell renal cell carcinoma.
Treatment: 89Zr-TLX250 PET/CT — 89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON Clinicaltrial.gov ID: NCT03849118)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Prior therapy
Cannot have received: chemotherapy
Chemotherapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: radiotherapy
Radiotherapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: targeted therapy
Targeted therapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: immunotherapy
Immunotherapy ... within 4 weeks prior to the planned administration of 89Zr -TLX250 or continuing adverse effects (> grade 1) from such therapy
Cannot have received: murine or chimeric antibody
Exposure to murine or chimeric antibodies within the last 5 years
Cannot have received: radionuclide
Previous administration of any radionuclide within 10 half-lives of the same
Cannot have received: experimental diagnostic or therapeutic drug
Exposure to any experimental diagnostic or therapeutic drug within 4 weeks or 5 half-lives (whichever is longer) from the date of planned administration of 89Zr-TLX250
Lab requirements
Kidney function
glomerular filtration rate (gfr) > 45 ml/min/1.73 m²
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06750419 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages